Infective Endocarditis After Transcatheter versus Surgical Aortic Valve Replacement.

Infective endocarditis SAVR TAVR heart surgery prognosis

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
08 Aug 2023
Historique:
received: 01 05 2023
revised: 27 07 2023
accepted: 04 08 2023
medline: 8 8 2023
pubmed: 8 8 2023
entrez: 8 8 2023
Statut: aheadofprint

Résumé

Scarce data are available comparing infective endocarditis (IE) following surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). This study aimed to compare the clinical presentation, microbiological profile, management, and outcomes of IE after SAVR vs. TAVR. Data were collected from the "Infectious Endocarditis after TAVR International" (enrollment from 2005 to 2020) and the "International Collaboration on Endocarditis" enrollment from 2000 to 2012) registries. Only patients with an IE affecting the aortic valve prosthesis were included. A 1:1 paired matching approach was used to compare patients with TAVR and SAVR. A total of 1688 patients were included. Of them, 602 (35.7%) had a surgical bioprosthesis (SB), 666 (39.5%) a mechanical prosthesis, 70 (4.2%) a homograft, and 350 (20.7%) a transcatheter heart valve. In the SAVR vs. TAVR matched population, the rate of new moderate or severe aortic regurgitation was higher in the SB group (43.4% vs. 13.4%, p < 0.001), and fewer vegetations were diagnosed in the SB group (62.5% vs. 82%, p < 0.001). Patients with a SB had a higher rate of perivalvular extension (47.9% vs.27%, p < 0.001) and Staphylococcus Aureus was less common in this group (13.4% vs. 22%, p = 0.033). Despite a higher rate of surgery in patients with SB (44.4% vs. 26.8%, p < 0.001), 1-year mortality was similar (SB: 46.5%, TAVR: 44.8%, log-rank p = 0.697). Clinical presentation, type of causative microorganism and treatment differed between patients with an IE located on SB compared to TAVR. Despite these differences, both groups exhibited high and similar mortality at 1-year follow-up.

Sections du résumé

BACKGROUND BACKGROUND
Scarce data are available comparing infective endocarditis (IE) following surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). This study aimed to compare the clinical presentation, microbiological profile, management, and outcomes of IE after SAVR vs. TAVR.
METHODS METHODS
Data were collected from the "Infectious Endocarditis after TAVR International" (enrollment from 2005 to 2020) and the "International Collaboration on Endocarditis" enrollment from 2000 to 2012) registries. Only patients with an IE affecting the aortic valve prosthesis were included. A 1:1 paired matching approach was used to compare patients with TAVR and SAVR.
RESULTS RESULTS
A total of 1688 patients were included. Of them, 602 (35.7%) had a surgical bioprosthesis (SB), 666 (39.5%) a mechanical prosthesis, 70 (4.2%) a homograft, and 350 (20.7%) a transcatheter heart valve. In the SAVR vs. TAVR matched population, the rate of new moderate or severe aortic regurgitation was higher in the SB group (43.4% vs. 13.4%, p < 0.001), and fewer vegetations were diagnosed in the SB group (62.5% vs. 82%, p < 0.001). Patients with a SB had a higher rate of perivalvular extension (47.9% vs.27%, p < 0.001) and Staphylococcus Aureus was less common in this group (13.4% vs. 22%, p = 0.033). Despite a higher rate of surgery in patients with SB (44.4% vs. 26.8%, p < 0.001), 1-year mortality was similar (SB: 46.5%, TAVR: 44.8%, log-rank p = 0.697).
CONCLUSIONS CONCLUSIONS
Clinical presentation, type of causative microorganism and treatment differed between patients with an IE located on SB compared to TAVR. Despite these differences, both groups exhibited high and similar mortality at 1-year follow-up.

Identifiants

pubmed: 37552784
pii: 7239252
doi: 10.1093/cid/ciad464
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Vassili Panagides (V)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Guillermo Cuervo (G)

Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.

Jaume Llopis (J)

Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain.

Mohamed Abdel-Wahab (M)

Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Norman Mangner (N)

Herzzentrum Dresden, Department of Internal Medicine and Cardiology, Technische Universität Dresden, Germany.

Gilbert Habib (G)

Cardiology Department, APHM, La Timone Hospital, Marseille, France.

Ander Regueiro (A)

Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.

Carlos Mestres (C)

Department of Cardiac Surgery, University Hospital Zürich, Zürich, Switzerland.

Pilar Tornos (P)

Department of Cardiology, Hospital Quiron Barcelona, Spain.

Eric Durand (E)

Normandie Univ, UNIROUEN, U1096, Department of Cardiology, CHU Rouen, France.

Christine Selton-Suty (C)

Department of Cardiology, University Hospital of Nancy, Nancy, France.

Nikolaj Ihlemann (N)

Righospitalet, Copenhagen, Denmark.

Niels Bruun (N)

Zealand University Hospital, Roskilde, Denmark.

Marina Urena (M)

Cardiology Department, Bichat Hospital, Paris, France.

Enrico Cecchi (E)

Cardiology Department, Hospital Maria Vittoria, Turin, Italy.

Holger Thiele (H)

Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Emanuele Durante-Mangoni (E)

Internal Medicine, University of Campania 'L Vanvitelli', and AORN dei Colli-Monaldi Hospital, Napoli, Italy.

Costanza Pellegrini (C)

Deutsches Herzzentrum München, Munich, Germany.

Helene Eltchaninoff (H)

Normandie Univ, UNIROUEN, U1096, Department of Cardiology, CHU Rouen, France.

Eugene Athan (E)

Department of Infectious Disease, Barwon Health, Deakin University, Geelong, VIC, Australia.

Lars Søndergaard (L)

Righospitalet, Copenhagen, Denmark.

Axel Linke (A)

Herzzentrum Dresden, Department of Internal Medicine and Cardiology, Technische Universität Dresden, Germany.

Pierre Tattevin (P)

Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.

David Del Val (D)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Eduard Quintana (E)

Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.

Vivian Chu (V)

Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.

Josep Rodés-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.

Jose M Miro (JM)

Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.
CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.

Classifications MeSH